TY  - GEN
AU  - Congregado, Belen
AU  - Rivero, Ines
AU  - Osman, Ignacio
AU  - Saez, Carmen
AU  - Medina Lopez, Rafael
PY  - 2022
DO  - 10.3390/biomedicines10061416
SN  - 2227-9059
UR  - http://hdl.handle.net/10668/20836
T2  - Biomedicines
AB  - The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of synthetic lethality, have been approved for prostate...
LA  - en
PB  - MDPI AG
KW  - PARP inhibitors
KW  - mutation test
KW  - prostate cancer
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Synthetic Lethal Mutations
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Precision Medicine
KW  - Patient Selection
KW  - Mutation
TI  - PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
TY  - review
VL  - 10
ER  -